Ibandronate Sodium Tablet, Film Coated
NDC Package 65862-237-26
Package Information
Ibandronate Sodium tablets are contraindicated in patients with the following conditions:Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see Warnings and Precautions [5.1]) Inability to stand or sit upright for at least 60 minutes (see Dosage and Administration [2.2], and Warnings and Precautions [5.1])Hypocalcemia (see Warnings and Precautions [5.2])Known hypersensitivity to ibandronate sodium tablets or to any of its excipients. This formulation utilizes a tablet, film coated delivery system. Marketed by Aurobindo Pharma Limited, this product is identified by NDC 65862-237 and is authorized under FDA application ANDA204502.
Identification & Billing
- RxCUI: 904932 - ibandronate sodium 150 MG Oral Tablet
- RxCUI: 904932 - ibandronic acid 150 MG Oral Tablet
- RxCUI: 904932 - ibandronic acid 150 MG (as ibandronate sodium 168.75 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 65862 - Aurobindo Pharma Limited
- 65862-237 - Ibandronate Sodium
- 65862-237-26 - 2500 TABLET, FILM COATED in 1 BAG
- 65862-237 - Ibandronate Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (65862-237). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 65862-237-26 identifies a specific commercial package of 2500 tablet, film coated in 1 bag of Ibandronate Sodium, a human prescription drug labeled by Aurobindo Pharma Limited. This tablet, film coated is formulated for oral use and contains ibandronate sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aurobindo Pharma Limited on March 11, 2016. The current certification is valid through December 31, 2027.
How is this Aurobindo Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 65862023726. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.